Drug Profile
Research programme: biologics - Adlai Nortye
Alternative Names: AN 3015; AN 6005Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Adlai Nortye
- Class Antibodies; Antineoplastics; Hepatoprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in China
- 28 Dec 2021 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in China
- 28 Nov 2017 Early research in Cancer in China (unspecified route)